Tenax Therapeutics to Present at the 36th Annual Roth Conference
12 Marzo 2024 - 1:30PM
Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3,
development-stage pharmaceutical company focused on identifying,
developing and commercializing products that address cardiovascular
and pulmonary diseases with high unmet medical need, today
announced that it will participate in the 36th Annual Roth
Conference in Dana Point, California, from March 17-19, 2024.
Tenax’s CEO, Chris Giordano, will provide an update on the company
and the ongoing development of levosimendan, in a conference
session investors can attend in person, or via webcast.
Format: Fireside Chat
Presenter: Chris Giordano, President & Chief
Executive OfficerDate and time: March 18, 2024 at
3:00 pm PDT Location: The Ritz-Carlton, Laguna
NiguelWebcast: Click here
Tenax Therapeutics’ management will also
participate in one-on-one investor meetings. Attendees may request
meetings during the conference by contacting their Roth
representative.
The live and archived webcast of the presentation
will be accessible from the Company’s investor relations
webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3,
development-stage pharmaceutical company focused on identifying,
developing, and commercializing products that address
cardiovascular and pulmonary diseases with high unmet medical need.
The Company owns global rights to develop and commercialize
levosimendan. Tenax also is developing a unique oral formulation of
imatinib. For more information, visit www.tenaxthera.com. Tenax’s
common stock is listed on The Nasdaq Stock Market LLC under the
symbol “TENX”.
Contacts
Investor Contact:John FrauncesManaging
DirectorLifeSci Advisors, LLCC: 917-355-2395, or
Brian MullenLifeSci Advisors, LLCC:
203-461-1175
Grafico Azioni Tenax Therapeutics (NASDAQ:TENX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Tenax Therapeutics (NASDAQ:TENX)
Storico
Da Dic 2023 a Dic 2024